ArticleArXiv2025
Hybrid artificial intelligence echogenic components-based diagnosis of adnexal masses on ultrasound.
Article in ArXiv, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
9 authors.
Funding
Abstract
Background: Adnexal masses are heterogeneous and have varied sonographic presentations, making them difficult to diagnose correctly. Purpose: Our study aimed to develop an innovative hybrid artificial intelligence/computer aided diagnosis (AI/CADx)-based pipeline to distinguish between benign and malignant adnexal masses on ultrasound imaging based upon automatic segmentation and echogenic-based classification. Methods: The retrospective study was conducted on a consecutive dataset of patients with an adnexal mass. There was one image per mass. Mass borders were segmented from the background Results: The cohort included 133 patients with 136 adnexal masses. In distinguishing between malignant and benign masses, the pipeline achieved an AUC of 0.90 [0.84, 0.95] on the training/validation set and 0.93 [0.83, 0.98] on the independent test set. Strong diagnostic performance was observed at the target 95% sensitivity. Conclusions: A novel hybrid AI/CADx echogenic components-based ultrasound imaging pipeline can distinguish between malignant and benign adnexal masses with strong diagnostic performance.
Identifiers
40321943PMC12047942What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.